Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model

BACKGROUND: Patients with stable coronary artery disease (CAD) constitute a heterogeneous group in which the treatment benefits by angiotensin‐converting enzyme (ACE)‐inhibitor therapy vary between individuals. Our objective was to integrate clinical and pharmacogenetic determinants in an ultimate c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Am Heart Assoc
Hauptverfasser: Oemrawsingh, Rohit M., Akkerhuis, K. Martijn, Van Vark, Laura C., Redekop, W. Ken, Rudez, Goran, Remme, Willem J., Bertrand, Michel E., Fox, Kim M., Ferrari, Roberto, Danser, A.H. Jan, de Maat, Moniek, Simoons, Maarten L., Brugts, Jasper J., Boersma, Eric
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2016
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943245/
https://ncbi.nlm.nih.gov/pubmed/27021566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.115.002688
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge